Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942261 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1HTTGAA | |
| SCHEMBL16992887 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1HTTMEN1 | |
| SCHEMBL29606539 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1HTTGAA | |
| SCHEMBL30625727 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1HTTMEN1 | |
| SCHEMBL2083152 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1HTTCYP3A4 | |
| SCHEMBL12065144 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHRTDP1HTTGAA | |
| Ammonia Solution, Strong SCHEMBL27652614 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHRTDP1HTTGAA | |
| SCHEMBL1663659 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TSHRTDP1HTTGAA | |
| SCHEMBL7408717 | 0.77 | ALDH1A1 (0.45) | ALDH1A1HTTCYP3A4MEN1KMT2A | |
| SCHEMBL31073706 | 0.77 | ALDH1A1 (0.45) | ALDH1A1HTTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240166601-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| EP-4212513-A1 | 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE DERIVATIVES AND RELATED COMPOUNDS AS NLRX1 LIGANDS FOR TREATING INFLAMMATORY DISEASES | LANDOS BIOPHARMA, INC. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11680045-B2 | NLRX1 ligands | LANDOS BIOPHARMA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| CN-1245496-A | 3-pyridyl enantiomers and their use as analgesics | ABBOTT LAB (US) | 2000-02-23 | — | — | CN | disclosed |
| EP-0970083-A1 | 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998037082-A1 | 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1998-08-27 | — | — | WO | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0846114-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5733912-A | NERVOUS SYSTEM DISORDERS IN NERVE CELLS | ABBOTT LABORATORIES (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1996040682-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680045-B2 | NLRX1 ligands | NLRP1, NLRP3, NOD1 | ALDH1A1 4423/4885TSHR 2986/4885TDP1 2746/4885 |
| US-20240166601-A1 | NLRX1 LIGANDS | NLRP1, NLRP3, NOD1 | ALDH1A1 4423/4885TSHR 2986/4885TDP1 2746/4885 |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | ALDH1A1 3263/4885TSHR 997/4885TDP1 3147/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | ALDH1A1 3576/4885TSHR 3945/4885TDP1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.